Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.
Harvard Medical School, Boston, MA.
Blood. 2023 Jan 26;141(4):391-405. doi: 10.1182/blood.2022016892.
Long noncoding RNAs (lncRNAs) can drive tumorigenesis and are susceptible to therapeutic intervention. Here, we used a large-scale CRISPR interference viability screen to interrogate cell-growth dependency to lncRNA genes in multiple myeloma (MM) and identified a prominent role for the miR-17-92 cluster host gene (MIR17HG). We show that an MIR17HG-derived lncRNA, named lnc-17-92, is the main mediator of cell-growth dependency acting in a microRNA- and DROSHA-independent manner. Lnc-17-92 provides a chromatin scaffold for the functional interaction between c-MYC and WDR82, thus promoting the expression of ACACA, which encodes the rate-limiting enzyme of de novo lipogenesis acetyl-coA carboxylase 1. Targeting MIR17HG pre-RNA with clinically applicable antisense molecules disrupts the transcriptional and functional activities of lnc-17-92, causing potent antitumor effects both in vitro and in vivo in 3 preclinical animal models, including a clinically relevant patient-derived xenograft NSG mouse model. This study establishes a novel oncogenic function of MIR17HG and provides potent inhibitors for translation to clinical trials.
长链非编码 RNA(lncRNAs)可驱动肿瘤发生,且易受到治疗干预。在此,我们利用大规模的 CRISPR 干扰存活筛选,在多发性骨髓瘤(MM)中探究了 lncRNA 基因对细胞生长的依赖性,并确定了 miR-17-92 簇宿主基因(MIR17HG)的重要作用。我们表明,一种由 MIR17HG 衍生的 lncRNA,命名为 lnc-17-92,是主要的细胞生长依赖性介质,其作用方式不依赖于 microRNA 和 DROSHA。lnc-17-92 为 c-MYC 和 WDR82 之间的功能相互作用提供了染色质支架,从而促进了编码从头合成脂肪生成乙酰辅酶 A 羧化酶 1 的限速酶 ACACA 的表达。用临床应用的反义分子靶向 MIR17HG 前 RNA,可破坏 lnc-17-92 的转录和功能活性,在包括具有临床相关性的患者来源异种移植 NSG 小鼠模型在内的 3 种临床前动物模型中,均在体外和体内产生强烈的抗肿瘤作用。本研究确立了 MIR17HG 的一种新的致癌功能,并为转化为临床试验提供了有效的抑制剂。